​

Funding Round

Series A - GentiBio

Series A - GentiBio

Investment Firm

Overview

GentiBio is a biotherapeutics company developing engineered regulatory T cells programmed to treat autoimmune allergic diseases.

Announced Date

Aug 11, 2021

Funding Type

Series A

Highlights

Location

United States, North America

Social

Investor Lead

N/A

Participant Investors

6

Investor Name
Participant InvestorJDRF T1D Fund
Participant InvestorRA Capital Management
Participant InvestorOrbiMed
Participant InvestorSeattle Children’s
Participant InvestorNovartis Venture Fund

Round Details and Background

GentiBio raised $157000000 on 2021-08-11 in Series A

GentiBio is a biotherapeutics company developing engineered regulatory T cells programmed to treat autoimmune allergic diseases.

Company Funding History

2

Announcment DateTransaction NameNumber Of InvestorsLead InvestorMoney Raised
Aug 05, 2020
Seed Round - GentiBio
3-20.0M
Aug 11, 2021
Series A - GentiBio
7-157.0M

Recent Activity

News

Aug 11, 2021

JDRF T1D Fund - GentiBio Announces $157M Series A Financing to Advance Engineered Regulatory T cells as Transformative Therapeutics with Potential to Restore Immune Tolerance and Durably Treat Autoinflammation